Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06934057 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

Study acronym: CABOLD
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2025 to May 16, 2025
    • Site details revised at 7 of 7 sites
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer
Trial Details
NCT Number NCT06934057
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: Ipsen
Conditions
(from sponsor)		 Kidney Cancer, Renal Cell Cancer
Related terms Carcinoma, Renal Cell, Kidney Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov